BiondVax Announces First Quarter 2022 Financial Results and Provides Business Update

Cindy Apt

JERUSALEM, June 1, 2022 /PRNewswire/ —  BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceuticals company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today published its first quarter financial results for the quarter ended March 31, 2022 and provided a business update.

BiondVax Pharmaceuticals Logo

BiondVax Pharmaceuticals Logo

Business Update

  • Development of the NanoAb program is proceeding according to plan:
       o  Demonstrated successful technology transfer from the Max Planck Institute for Multidisciplinary Sciences (MPG) to BiondVax’s manufacturing facility in Jerusalem. Testing showed that BiondVax was able to successfully manufacture its first exclusively licensed NanoAb for the treatment of COVID–19 and demonstrated strong neutralization of live COVID–19 virus in–vitro at levels similar to those demonstrated by NanoAbs originally produced at MPG.
       o   The NanoAbs produced at BiondVax’s facility demonstrated similarly strong COVID–19 in–vitro neutralization capacity after being sprayed through a medical device inhaler that is expected to be used in the first in-human clinical trials planned for 2023.
       o   A new NanoAb targeting Omicron that was generated at MPG was recently shown to successfully neutralize the Omicron variant of COVID–19 in–vitro. This NanoAb is expected to be manufactured and used in BiondVax’s first in–human clinical trials.

  • Our team of 26 full–time employees includes 12 new employees who joined BiondVax in 2022 to support all aspects of BiondVax’s NanoAb program, including quality assurance, quality control, R&D, manufacturing, preclinical and clinical trials.

  • In April and May, BiondVax hosted two investor webinars and presented in person at the Biomed Israel and HC Wainwright Global Investment conferences.

First Quarter 2022 Financial Summary

Results are in New Israel Shekels (NIS) and convenience translation to $US is provided using the exchange rate of 3.176 (NIS/$US), the rate as of the close of business on March 31, 2022.

  • Total operating expenses for the three months ended March 31, 2022 were NIS 8.3 million ($2.6 million) compared to NIS 6.8 million for the three months ended March 31, 2021.

  • R&D expenses for the three months ended March 31, 2022 were NIS 3.65 million ($1.1 million) compared to NIS 2.8 million for the three months ended March 31, 2021. This increase was primarily due to activity related to the new NanoAb program.

  • Marketing, general and administrative expenses for the three months ended March 31, 2022 were NIS 4.6 million ($1.5 million) compared to NIS 4.0 million for the three months ended March 31, 2021.

As of March 31, 2022, BiondVax had cash and cash equivalents of NIS 48.9 million ($15.4 million) as compared to NIS 54.0 million as of December 31, 2021.

Unaudited first quarter financial results will be submitted to the Securities and Exchange Commission. A summary is included in the tables below.

About BiondVax

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses. Since its inception, the company has executed eight clinical trials including a seven country, 12,400 participant Phase 3 trial of its vaccine candidate and has built a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody (NanoAb) pipeline. For more information, please visit www.biondvax.com.

Contact Details

Company: Joshua E. Phillipson | +972 8 930 2529 | [email protected]
Investor Relations: Kenny Green | +1 212 378 8040 | [email protected]

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as “expect,” “believe,” “intend,” “plan,” “continue,” “may,” “will,” “anticipate,” and similar expressions are intended to identify forward-looking statements. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements regarding the timing of future clinical trials, the therapeutic and commercial potential of NanoAbs and execution of a definitive amendment agreement with EIB. These forward-looking statements reflect management’s current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected by the management of BiondVax Pharmaceuticals Ltd. Risks and uncertainties include, but are not limited to, the risk that the therapeutic and commercial potential of NanoAbs will not be met; the risk of a delay in the preclinical and clinical data for NanoAbs, if any; the risk that BiondVax and EIB will not reach agreement with respect to the restructuring of the loan from European Investment Bank; the risk that BiondVax may not be able to secure additional capital on attractive terms, if at all; the risk that the European Investment Bank may accelerate the loans under its finance contract with BiondVax; risks relating to the COVID-19 (coronavirus) pandemic; BiondVax’s ability to acquire rights to additional product opportunities; BiondVax’s ability to enter into collaborations on terms acceptable to BiondVax or at all; timing of receipt of regulatory approval of BiondVax’s manufacturing facility in Jerusalem, if at all or when required; the risk that the manufacturing facility will not be able to be used for a wide variety of applications and other vaccine and treatment technologies, and the risk that drug development involves a lengthy and expensive process with uncertain outcomes. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 25, 2022. BiondVax undertakes no obligation to revise or update any forward-looking statement for any reason.

 

 

 

BALANCE SHEETS

In thousands, except share and per share data

Convenience

Translation

December 31,

March 31,

March 31,

2021

2021

2022

2022

Audited

Unaudited

Unaudited

N I S 

U.S. dollars

CURRENT ASSETS:

Cash and cash equivalents

54,036

48,577

48,886

15,391

Other receivables

1,012

481

619

196

55,048

49,058

49,505

15,587

LONG–TERM ASSETS:

Property, plant and equipment

38,519

39,252

39,745

12,514

Right-of-use assets

5,588

5,978

5,359

1,687

Other long-term assets

444

436

929

293

44,551

45,666

46,033

14,494

99,599

94,724

95,538

30,081

CURRENT LIABILITIES:

Trade payables

3,107

2,085

4,102

1,292

Operating lease liabilities

773

641

802

253

Loan from others

62,346

Other payables

3,327

1,640

3,598

1,133

7,207

66,712

8,502

2,677

LONG–TERM LIABILITIES:

Operating lease liabilities

5,712

5,978

5,585

1,759

Loan from others

63,252

65,187

20,524

Other payables

1,135

Severance pay liability, net

95

95

95

30

69,059

7,208

70,867

22,313

SHAREHOLDERS’ EQUITY:

     Ordinary shares of no par value: Authorized:
          1,800,000,000 and 700,000,000 shares at  
          March 31, 2022 December 31, 2021 and
          March 31, 2021, respectively; Issued and
          outstanding: 745,048,544 , 739,048,544 and
          573,285,824  shares March 31, 2022,
          December 31, 2021 and  March 31, 2021,
          respectively

*)   –

*)   –

*)   –

*)   –

Share premium

388,104

353,783

390,356

122,908

Accumulated deficit

(364,771)

(332,979)

(374,187)

(117,817)

23,333

20,804

16,169

5,091

99,599

94,724

95,538

30,081

*)                    Represents less than NISUSD 1.

 

 

STATEMENTS OF COMPREHENSIVE LOSS

In thousands, except share and per share data

Convenience

translation

Year ended

December 31,

Three months ended

March 31,

Three months
ended

March 31,

2021

2021

2022

2022

Audited

Unaudited

Unaudited

NIS

U.S. dollars

Operating expenses:

Research and development, net of
     participations

10,341

2,750

3,653

1,150

Marketing, general and administrative

24,528

4,005

4,633

1,459

Other income

(40)

Total operating expenses (income)

34,829

6,755

8,286

2,609

Operating income (loss)

(34,829)

(6,755)

(8,286)

(2,609)

Financial income

5,716

1,182

1,212

382

Financial expense

(10,865)

(2,613)

(2,342)

(737)

Net loss and total comprehensive loss  

(39,978)

(8,186)

(9,416)

(2,965)

 

Basic and Diluted net loss per share

(0.07)

(0.02)

(0.02)

(0.005)

Weighted average number of shares
     outstanding used to compute basic
     and diluted loss per share

564,575,967

530,840,391

570,114,429

570,114,429

 

The notes in the Company’s quarterly report are an integral part of the financial statements. The complete financial results are available in the Form 6-K to be filed with the Securities and Exchange Commission.

Logo – https://mma.prnewswire.com/media/615570/BiondVax_Pharmaceuticals_Logo.jpg

 

Cision

Cision

View original content:https://www.prnewswire.com/news-releases/biondvax-announces-first-quarter-2022-financial-results-and-provides-business-update-301558814.html

SOURCE BiondVax Pharmaceuticals Ltd.

https://finance.yahoo.com/news/biondvax-announces-first-quarter-2022-111000359.html

Next Post

Surge in Business Loans Propels Profit at BMO, Scotiabank

(Bloomberg) — Bank of Nova Scotia and Bank of Montreal, Canada’s third- and fourth-largest lenders, got a boost last quarter as the nation’s businesses increased borrowing to meet customer demand. Most Read from Bloomberg Commercial-loan balances at Scotiabank’s domestic banking unit surged 19% to C$72.7 billion ($56.5 billion) and gained […]